178 related articles for article (PubMed ID: 35920686)
21. The distribution pattern of ERα expression, ESR1 genetic variation and expression of growth factor receptors: association with breast cancer prognosis in Russian patients treated with adjuvant tamoxifen.
Babyshkina N; Vtorushin S; Zavyalova M; Patalyak S; Dronova T; Litviakov N; Slonimskaya E; Kzhyshkowska J; Cherdyntseva N; Choynzonov E
Clin Exp Med; 2017 Aug; 17(3):383-393. PubMed ID: 27225751
[TBL] [Abstract][Full Text] [Related]
22. The variant T allele of PvuII in ESR1 gene is a prognostic marker in early breast cancer survival.
Houtsma D; de Groot S; Baak-Pablo R; Kranenbarg EM; Seynaeve CM; van de Velde CJH; Böhringer S; Kroep JR; Guchelaar H-; Gelderblom H
Sci Rep; 2021 Feb; 11(1):3249. PubMed ID: 33547330
[TBL] [Abstract][Full Text] [Related]
23. Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy.
Filipits M; Rudas M; Heinzl H; Jakesz R; Kubista E; Lax S; Schippinger W; Dietze O; Greil R; Stiglbauer W; Kwasny W; Nader A; Stierer M; Gnant MF;
Clin Cancer Res; 2009 Sep; 15(18):5888-94. PubMed ID: 19723645
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
[TBL] [Abstract][Full Text] [Related]
25. Oligonucleotide microarray analysis of estrogen receptor alpha-positive postmenopausal breast carcinomas: identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen.
Tozlu-Kara S; Roux V; Andrieu C; Vendrell J; Vacher S; Lazar V; Spyratos F; Tubiana-Hulin M; Cohen P; Dessen P; Lidereau R; Bièche I
J Mol Endocrinol; 2007 Oct; 39(4):305-18. PubMed ID: 17909269
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14.
Wolmark N; Mamounas EP; Baehner FL; Butler SM; Tang G; Jamshidian F; Sing AP; Shak S; Paik S
J Clin Oncol; 2016 Jul; 34(20):2350-8. PubMed ID: 27217450
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of ESR1 gene copy number changes in breast cancer as measured by fluorescence in situ hybridisation.
Lin CH; Liu JM; Lu YS; Lan C; Lee WC; Kuo KT; Wang CC; Chang DY; Huang CS; Cheng AL
J Clin Pathol; 2013 Feb; 66(2):140-5. PubMed ID: 23268322
[TBL] [Abstract][Full Text] [Related]
28. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.
Zundelevich A; Dadiani M; Kahana-Edwin S; Itay A; Sella T; Gadot M; Cesarkas K; Farage-Barhom S; Saar EG; Eyal E; Kol N; Pavlovski A; Balint-Lahat N; Dick-Necula D; Barshack I; Kaufman B; Gal-Yam EN
Breast Cancer Res; 2020 Feb; 22(1):16. PubMed ID: 32014063
[TBL] [Abstract][Full Text] [Related]
29. Estrogen receptor-alpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer.
Bostner J; Skoog L; Fornander T; Nordenskjöld B; Stål O
Clin Cancer Res; 2010 Mar; 16(5):1624-33. PubMed ID: 20179234
[TBL] [Abstract][Full Text] [Related]
30. 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
Buzdar AU;
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):399-403. PubMed ID: 14623537
[TBL] [Abstract][Full Text] [Related]
31. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer.
Bostner J; Ahnström Waltersson M; Fornander T; Skoog L; Nordenskjöld B; Stål O
Oncogene; 2007 Oct; 26(49):6997-7005. PubMed ID: 17486065
[TBL] [Abstract][Full Text] [Related]
32. The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8.
Filipits M; Rudas M; Kainz V; Singer CF; Fitzal F; Bago-Horvath Z; Greil R; Balic M; Regitnig P; Halper S; Hulla W; Egle D; Barron S; Loughman T; O'Leary D; Gallagher WM; Hlauschek D; Gnant M; Dubsky P
Clin Cancer Res; 2021 Nov; 27(21):5931-5938. PubMed ID: 34380638
[TBL] [Abstract][Full Text] [Related]
33. Quantitative in situ measurement of estrogen receptor mRNA predicts response to tamoxifen.
Bordeaux JM; Cheng H; Welsh AW; Haffty BG; Lannin DR; Wu X; Su N; Ma XJ; Luo Y; Rimm DL
PLoS One; 2012; 7(5):e36559. PubMed ID: 22606272
[TBL] [Abstract][Full Text] [Related]
34. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer.
Holst F; Stahl PR; Ruiz C; Hellwinkel O; Jehan Z; Wendland M; Lebeau A; Terracciano L; Al-Kuraya K; Jänicke F; Sauter G; Simon R
Nat Genet; 2007 May; 39(5):655-60. PubMed ID: 17417639
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
Bago-Horvath Z; Rudas M; Dubsky P; Jakesz R; Singer CF; Kemmerling R; Greil R; Jelen A; Böhm G; Jasarevic Z; Haid A; Gruber C; Pöstlberger S; Filipits M; Gnant M;
Clin Cancer Res; 2011 Dec; 17(24):7828-34. PubMed ID: 21998336
[TBL] [Abstract][Full Text] [Related]
36. Impact of estrogen receptor α on the tamoxifen response and prognosis in luminal-A-like and luminal-B-like breast cancer.
Babyshkina N; Vtorushin S; Dronova T; Patalyak S; Slonimskaya E; Kzhyshkowska J; Cherdyntseva N; Choynzonov E
Clin Exp Med; 2019 Nov; 19(4):547-556. PubMed ID: 31562548
[TBL] [Abstract][Full Text] [Related]
37. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
Jakesz R; Jonat W; Gnant M; Mittlboeck M; Greil R; Tausch C; Hilfrich J; Kwasny W; Menzel C; Samonigg H; Seifert M; Gademann G; Kaufmann M; Wolfgang J;
Lancet; 2005 Aug 6-12; 366(9484):455-62. PubMed ID: 16084253
[TBL] [Abstract][Full Text] [Related]
38. The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer.
Vitale SR; Ruigrok-Ritstier K; Timmermans AM; Foekens R; Trapman-Jansen AMAC; Beaufort CM; Vigneri P; Sleijfer S; Martens JWM; Sieuwerts AM; Jansen MPHM
BMC Cancer; 2022 Feb; 22(1):165. PubMed ID: 35151276
[TBL] [Abstract][Full Text] [Related]
39. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
Bostner J; Alayev A; Berman AY; Fornander T; Nordenskjöld B; Holz MK; Stål O
Breast Cancer Res Treat; 2018 Feb; 168(1):17-27. PubMed ID: 29128895
[TBL] [Abstract][Full Text] [Related]
40. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma.
Bièche I; Girault I; Urbain E; Tozlu S; Lidereau R
Breast Cancer Res; 2004; 6(3):R252-63. PubMed ID: 15084249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
